51357-73-4

Usage

Uses

Used in Pharmaceutical Industry:
N-[(E)-biphenyl-4-ylmethylidene]aniline is used as a key intermediate in the synthesis of various pharmaceuticals, contributing to the development of new drugs and medications.
Used in Dye and Pigment Industry:
N-[(E)-biphenyl-4-ylmethylidene]aniline is utilized as an important building block in the production of dyes and pigments, playing a crucial role in the coloration of various materials and products.
Used in Organic Chemical Synthesis:
N-[(E)-biphenyl-4-ylmethylidene]aniline serves as a versatile intermediate for the synthesis of a wide range of organic compounds, enabling the creation of complex molecules and materials.
Used in Research and Development:
It is extensively used in research and development settings as a starting material for the synthesis of more complex organic compounds and materials, driving innovation in the chemical and materials sciences.
It is crucial to handle N-[(E)-biphenyl-4-ylmethylidene]aniline with care, as it can be harmful if not used properly, ensuring safety in its applications across different industries.

Upstream product

• 2362-79-0 N-(4-chlorobenzylidene)aniline 
• 100-58-3 phenylmagnesium bromide 
• 62-53-3 aniline 
• 873-76-7 para-Chlorobenzyl alcohol 
• 3597-91-9 biphenyl-4-yl methanol 

Downstream Products

• 16143-33-2 2-[4-(trans-2-biphenyl-4-yl-vinyl)-phenyl]-naphtho[1,2-d]oxazole 
• 16178-33-9 2-[4-(trans-2-biphenyl-4-yl-vinyl)-phenyl]-benzothiazole 
• 16256-12-5 2-[4-(trans-2-biphenyl-4-yl-vinyl)-phenyl]-naphtho[2,1-d]oxazole 
• 16177-93-8 6-(trans-2-biphenyl-4-yl-vinyl)-2-(4-tert-butyl-phenyl)-benzooxazole 
• 16178-00-0 2-biphenyl-4-yl-6-(trans-2-biphenyl-4-yl-vinyl)-5-methyl-benzooxazole 
• 16178-23-7 4,5-bis-[4-(trans-2-biphenyl-4-yl-vinyl)-phenyl]-2-phenyl-oxazole 
• 16157-42-9 2-[4-(trans-2-biphenyl-4-yl-vinyl)-phenyl]-5-(4-trans-styryl-phenyl)-[1,3,4]oxadiazole 
• 16253-68-2 2-[4-(trans-2-biphenyl-4-yl-vinyl)-phenyl]-6-methyl-benzooxazole 
• 16178-11-3 2-[4-(2-biphenyl-4-yl-vinyl)-phenyl]-5-phenyl-oxazole 
• 16178-28-2 5-[4-(trans-2-biphenyl-4-yl-vinyl)-phenyl]-3-phenyl-isoxazole 
• 23843-18-7 trans-2,3-Bis-(4-phenyl-styryl)-naphthalin 
• 23802-60-0 trans-1,6-Bis-(4-phenyl-styryl)-naphthalin 
• 23820-40-8 trans-4,4'-Bis-<4-phenyl-styryl>-biphenyl 
• 16726-79-7 trans-1-(4-Phenyl-styryl)-4-stryl-benzol 

Relevant academic research and scientific papers

Structures and catalytic oxidative coupling reaction of four Co-MOFs modified with R-isophthalic acid (R=H, OH and COOH) and trigonal ligands

In this paper, we present fourCo-MOFsusing R-substituted isophthalic acid (R-H2BDC, R = H, OH and COOH) along with trigonaln-TBT (n= 3 or 4) as organic ligands. TheseCo-MOFsare formulated as {[Co(1,3-BDC)(4-TBT)2/3]·(H2O)(DMF)1.5}n(Co-MOF-1), {[Co(HO-BDC)(4-TBT)]·(EtOH)2(DMF)2}n(Co-MOF-2), {[Co(HO-BDC)(4-TBT)2/3]·(H2O)3(MeOH)3(DMA)}n(Co-MOF-3) and{[Co3(BTC)2(3-TBT)2(H2O)2]·(H2O)2(EtOH)5(DMA)1.5}n(Co-MOF-4), where H2BDC = isophthalic acid, OH-H2BDC = 5-hydroxyisophthalic acid and H3BTC = 1,3,5-tricarboxybenzene, 4-TBT = 1,3,5- tris(4-pyridyl)benzene and 3-TBT = 1,3,5-tris(3-pyridyl)benzene.Co-MOF-1,2and3are constructed from the dimeric Co2(COO)2unit and exhibit 3D frameworks. InCo-MOF-4, the dimeric Co2(COO)2unit and single nuclear CoIIcenter are connected by BTC3?and 3-TBT ligands into a 3D network. The catalytic experiments revealed that fourCo-MOFscan catalyze the oxidative coupling reaction of benzyl alcohols and aniline to imines with good to excellent conversions under solvent-free conditions and an air atmosphere.Co-MOF-4exhibited the best catalytic performance and the catalyst could be reused for at least five cycles without losing its structural integrity and catalytic activity.

Inherent vs Apparent Chemoselectivity in the Kumada-Corriu Cross-Coupling Reaction

The Kumada-Corriu reaction is a powerful tool for C-C bond formation, but is seldom utilized due to perceived chemoselectivity issues. Herein, we demonstrate that high-yielding couplings can occur in the presence of many electrophilic and heterocyclic functional groups. Our strategy is mechanically based, matching oxidative addition rates with the rate of syringe pump addition of the Grignard reagent. The mechanistic reason for the effectiveness of this strategy is uncovered by continuous-infusion ESI-MS studies.